^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Norepinephrine reuptake inhibitor

    Related drugs:
    1d
    MACS-2: Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    amitriptyline
    1d
    MACS-1: Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (clinicaltrials.gov)
    P2, N=50, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    amitriptyline
    6d
    Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Cairo University
    New trial
    6d
    A Study of CSTI-500 in Patients With Prader-Willi Syndrome (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, ConSynance Therapeutics
    New P2 trial
    8d
    Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (clinicaltrials.gov)
    P3, N=422, Active, not recruiting, University of Rochester NCORP Research Base | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    10d
    Tramadol induced hypoxia signaling and paraptosis-like cell death in breast cancer cells via HIF-1α and ATF4 dependent pathways. (PubMed, Redox Rep)
    Notably, the knockout of HIF-1α or ATF4 significantly reduced tramadol-induced cytotoxicity, highlighting their crucial roles in mediating these cellular responses. Tramadol induced breast cancer cell death via paraptosis which highlights its therapeutic potential in targeting resistant cancer subtypes such as triple-negative breast cancer.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • ATF4 (Activating Transcription Factor 4)
    11d
    Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study. (PubMed, Int Psychogeriatr)
    Inflammatory and neuronal injury biomarkers may have prognostic value and may potentially inform treatment response and remission outcomes in apathy. Apathy in Dementia Methylphenidate Trial 2 (ADMET2), NCT02346201, https://clinicaltrials.gov/study/NCT02346201.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • S100B (S100 Calcium Binding Protein B)
    14d
    Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, University of Minnesota | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    I-COAP: Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (clinicaltrials.gov)
    P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Dec 2031 --> Dec 2029 | Trial primary completion date: Dec 2030 --> Jul 2029
    Trial completion date • Trial primary completion date
    14d
    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD (clinicaltrials.gov)
    P4, N=286, Recruiting, Supernus Pharmaceuticals, Inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    14d
    The Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients (clinicaltrials.gov)
    P=N/A, N=175, Not yet recruiting, Bilecik Seyh Edebali Universitesi
    New trial
    15d
    Bupropion for the Prevention of Postpartum Smoking Relapse (clinicaltrials.gov)
    P4, N=200, Recruiting, University of Minnesota | Trial primary completion date: Jan 2026 --> Jul 2026 | Trial completion date: Jan 2026 --> Jul 2026
    Trial completion date • Trial primary completion date